News Article

Spire Healthcare’s board has confirmed it is “actively evaluating appropriate action that could drive long-term shareholder value,” appointing Rothschild & Co to examine avenues that include a potential sale of the UK’s second-largest private hospital operator.

The announcement triggered an immediate market response: Spire shares jumped as much as 13 % to 245p, lifting the group’s market capitalisation to £872m before dropping. The board has emphasised that it has received no approaches and that any discussions remain “highly preliminary”.

The timing blends opportunity and risk. NHS waiting-list pressures have funnelled more insured and self-pay patients to private providers, supporting volume growth across Spire’s 38 hospitals and 50-plus clinics. The company warned in March, however, that wage, National Insurance and energy costs could trim 2025 EBITDA by up to £30m, tempering margin expansion despite rising demand.

Any sale process may reshape the competitive landscape in UK acute care, potentially drawing interest from infrastructure funds or global hospital groups attracted to Spire’s asset base and NHS outsourcing tailwinds.

Management has not set a timetable, and further updates will follow “as appropriate”.